Current corticosteroid therapeutic strategy for community-acquired pneumonia in adults: indications, dosage, and timing
Study context
- Population
- Adults with community-acquired pneumonia
- Comparison
- Corticosteroids as adjunctive therapy in community-acquired pneumonia (CAP)
Main finding
As reported in the abstract
- Recent major guidelines on CAP, sepsis, acute respiratory distress syndrome (ARDS) and critical illness-related corticosteroid insufficiency generally support corticosteroids in severe CAP
- REMAP-CAP RCT (2025) failed to demonstrate significant benefit
- Corticosteroid therapy should be individualised by CAP severity, particularly degree of hypoxemia and respiratory failure
- For nonbacterial pneumonia, strong evidence supports corticosteroids only for COVID-19 and Pneumocystis jirovecii pneumonia in HIV-infected individuals; observational data do not support use for influenza or fungal infections
- In CAP complicated by septic shock or ARDS, corticosteroids endorsed by recent guidelines; recommended timing, dosage and duration vary
Original publication
Current corticosteroid therapeutic strategy for community-acquired pneumonia in adults: indications, dosage, and timing. J Intensive Care. Published 1 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →